Trans-Pacific Technology Fund (TPTF)
VC Fund
Taipei, Taiwan
Trans-Pacific Technology Fund (TPTF) is a VC fund in Taipei focused on Health Care and Machine Learning. Our Mission:The Trans-Pacific Technology Fund (TPTF) is a technology-driven venture capital fund, investing in innovative companies shaping the future of global business. We work actively with the leadership of our portfolio companies from different regions of the world, supporting their growth.Our Approach:At TPTF, we believe the cornerstoneof every great company is great people. Before a fascinating innovation can become a game-changing company on a global scale, we believe there needs to be daring entrepreneurs to convert the concept into reality.In addition to providing capital, we consider ourselves a committed partner, supporting our entrepreneurs via our extensive international resources, deep domain expertise and, most importantly, our passion to work together to build great companies.Our Focus Area:We invest in disruptive, platform technologies focusing on the sectors where we have leading domain expertise, including but not limited to: advanced materials, health/life sciences, ICT, IOT and robotics/automation. We have a multi-stage investment strategy to work with companies ranging from early to expansion/late stage. Through our extensive network of collaborative partners around the world, we have a global investment scope, seeking to invest in companies across Asia, North America and Europe.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Trans-Pacific Technology Fund (TPTF) invests in
Stages Trans-Pacific Technology Fund (TPTF) invests in
Countries Trans-Pacific Technology Fund (TPTF) invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $3M–$4.2M
- Series C
- $20M–$400M
Investment Focus
Industry
- Health Care 3 (27%)
- Machine Learning 3 (27%)
- Biotechnology 2 (18%)
- Health Diagnostics 2 (18%)
- Artificial Intelligence 2 (18%)
Stage
- Series C 3 (27%)
- Seed 2 (18%)
- Pre-Seed 1 (9%)
- Series A 1 (9%)
- Series D 1 (9%)
Country
- Indonesia 3 (27%)
- United States 3 (27%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Barry Lee
Principal
|
Principal | Total investments: 1 | Find email | |
Lee Hsieh
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
Glenn Kline
Managing Partner
|
Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Rey.id is a new kind of insurance which serves you like your family doctor -- all from your gadget. We believe that insurance products can bring a better impression, not only as a means to play your health risk claims, but also serve a complete healthcare service, as well as improving your quality of life.Rey is the first health and lifeinsurance provider in Indonesia that is designed in a technology platform, as well as serves as an integrated digital healthcare ecosystem. Unlike your usual insurance products, Rey focuses on the quality of healthcare services and well-being of our members.Rey does not want to be transactional, but also transformational in helping you achieving a healthy life.We started Rey in 2021. We are a team of people with different backgrounds, expertises, and experiences, yet with the same purpose -- To reimagine and to democratize life & health insurance in Indonesia.We realize that today life & health insurance is a product that people need, but not a product that people want. Therefore, we design Rey as a life & health insurance product that we would want for ourselves -- A (w)holistic protection, technology-driven, focus on healthcare quality and our wellbeing, and never be a hassle. | $3.5M / Seed / Sep 30, 2024 | ||
| Rey.id is a new kind of insurance which serves you like your family doctor -- all from your gadget. We believe that insurance products can bring a better impression, not only as a means to play your health risk claims, but also serve a complete healthcare service, as well as improving your quality of life.Rey is the first health and lifeinsurance provider in Indonesia that is designed in a technology platform, as well as serves as an integrated digital healthcare ecosystem. Unlike your usual insurance products, Rey focuses on the quality of healthcare services and well-being of our members.Rey does not want to be transactional, but also transformational in helping you achieving a healthy life.We started Rey in 2021. We are a team of people with different backgrounds, expertises, and experiences, yet with the same purpose -- To reimagine and to democratize life & health insurance in Indonesia.We realize that today life & health insurance is a product that people need, but not a product that people want. Therefore, we design Rey as a life & health insurance product that we would want for ourselves -- A (w)holistic protection, technology-driven, focus on healthcare quality and our wellbeing, and never be a hassle. | $4.2M / Seed / Jul 06, 2022 | ||
| Rey.id is a new kind of insurance which serves you like your family doctor -- all from your gadget. We believe that insurance products can bring a better impression, not only as a means to play your health risk claims, but also serve a complete healthcare service, as well as improving your quality of life.Rey is the first health and lifeinsurance provider in Indonesia that is designed in a technology platform, as well as serves as an integrated digital healthcare ecosystem. Unlike your usual insurance products, Rey focuses on the quality of healthcare services and well-being of our members.Rey does not want to be transactional, but also transformational in helping you achieving a healthy life.We started Rey in 2021. We are a team of people with different backgrounds, expertises, and experiences, yet with the same purpose -- To reimagine and to democratize life & health insurance in Indonesia.We realize that today life & health insurance is a product that people need, but not a product that people want. Therefore, we design Rey as a life & health insurance product that we would want for ourselves -- A (w)holistic protection, technology-driven, focus on healthcare quality and our wellbeing, and never be a hassle. | $1M / Pre-Seed / Sep 12, 2021 | ||
| Prixa is a pioneer in digital healthcare that allows patients to manage their health more practically. They offer the health services companies need and make them accessible on one platform. Their comprehensive digital healthcare ecosystem, supported by artificial intelligence technology, functions as a digital healthcare provider, includingteleconsultation, doctor appointments, pharmacy delivery, lab tests, and content about health.Prixa.ai was founded in 2019 and is based in Jakarta, Indonesia. | $3M / Seed / Jun 04, 2021 | ||
| Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses inpatients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models.Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts. | $90M / Series D / Sep 17, 2020 | ||
| Finch Therapeutics is a mission-driven microbiome engineering company, is developing novel microbial therapies to serve patients with serious and unmet medical needs. The company uses machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses inpatients. This human-centric discovery model leverages clinical data to focus on in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. This enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models.Finch Therapeutics was founded in 2017 and is headquartered in Somerville, Massachusetts. | $53.5M / Series C / Aug 21, 2019 | ||
| Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more. | $400M / Series C / Dec 13, 2018 | ||
| At Heal, we believe improving health outcomes starts by meeting patients where they're most comfortable: at home. That’s why we provide value-based, in-home primary care to seniors on Medicare and select Medicare Advantage plans. Heal’s service model allows board-certified doctors and nurse practitioners to spend more time with their patients,so care is never rushed, and a strong patient-provider relationship is established.We serve seniors at all stages of their health journey, from preventive care -- like flu shots and annual physicals -- to treating common illnesses and managing chronic conditions. Our services also include telemedicine visits and remote health monitoring, so getting quality care when its needed is easier than ever.With easy and convenient phone support for scheduling or other questions, we offer appointments 8am-6pm, 7 days/week – including weekends and holidays. | $20M / Series C / May 22, 2018 | ||
| Kata.ai is an Indonesian Conversational Artificial Intelligence company with a focus on enhancing the understanding of human conversations, improving the way humans collaborate with machines. Kata.ai’s Natural Language Processing (NLP) technology powers intelligent chatbots (virtual customer service / virtual friend) for major corporations inIndonesia across a different kind of industries such as Unilever (FMCG) and Telkomsel (Telco).The company’s proprietary Kata Bot Platform can be leveraged to create engaging chatbots on top of Kata.ai’s robust and scalable AI technology platform, ensuring company of any size can easily build their own chatbot on any messaging platform.Established in 2015, the company has become a trusted partner for major corporations such as Microsoft, Accenture, and Line. In 2017, the company also received Series-A funding led by Trans-Pacific Technology Fund. | $3.5M / Series A / Aug 29, 2017 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Trans-Pacific Technology Fund (TPTF) invest in?
Trans-Pacific Technology Fund (TPTF) invests primarily in Health Care, Machine Learning and Biotechnology startups, most often at Series C and Seed stage. Most of the 11 investments tracked by Shizune back companies in Indonesia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Trans-Pacific Technology Fund (TPTF) invest in?
Trans-Pacific Technology Fund (TPTF) typically joins rounds of $3M–$4.2M at Seed and $20M–$400M at Series C. These are whole funding-round sizes, not Trans-Pacific Technology Fund (TPTF)'s own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Trans-Pacific Technology Fund (TPTF) took part in.
How do I contact Trans-Pacific Technology Fund (TPTF)?
Public channels for Trans-Pacific Technology Fund (TPTF) include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Trans-Pacific Technology Fund (TPTF)?
The team at Trans-Pacific Technology Fund (TPTF) includes Barry Lee (Principal), Lee Hsieh (Venture Partner) and Glenn Kline (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
